These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 33435837)

  • 1. Vasopressin antagonism in heart failure: a review of the hemodynamic studies and major clinical trials.
    Urbach J; Goldsmith SR
    Ther Adv Cardiovasc Dis; 2021; 15():1753944720977741. PubMed ID: 33435837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasopressin and Vasopressin Antagonists in Heart Failure.
    Vishram-Nielsen JK; Gustafsson F
    Handb Exp Pharmacol; 2017; 243():307-328. PubMed ID: 28432473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac output improvement by pecavaptan: a novel dual-acting vasopressin V1a/V2 receptor antagonist in experimental heart failure.
    Mondritzki T; Mai TA; Vogel J; Pook E; Wasnaire P; Schmeck C; Hüser J; Dinh W; Truebel H; Kolkhof P
    Eur J Heart Fail; 2021 May; 23(5):743-750. PubMed ID: 32946151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual Vasopressin V1a/V2 Antagonism: The Next Step in Neurohormonal Modulation in Patients With Heart Failure?
    Goldsmith SR; Udelson JE; Gheorghiade M
    J Card Fail; 2018 Feb; 24(2):112-114. PubMed ID: 29329950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentiation of arginine vasopressin antagonistic effects by selective V2 versus dual V2/V1a receptor blockade in a preclinical heart failure model.
    Mondritzki T; Kolkhof P; Sabbah HN; Gheorghiade M; Fürstner C; Schmeck C; Siedentop H; Schaefer S; Truebel H
    Am J Ther; 2011 Jan; 18(1):31-7. PubMed ID: 21192248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arginine vasopressin antagonism in heart failure: Current status and possible new directions.
    Goldsmith SR
    J Cardiol; 2019 Jul; 74(1):49-52. PubMed ID: 30904236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolvaptan: a selective vasopressin type 2 receptor antagonist in congestive heart failure.
    Rangasetty UC; Gheorghiade M; Uretsky BF; Orlandi C; Barbagelata A
    Expert Opin Investig Drugs; 2006 May; 15(5):533-40. PubMed ID: 16634691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vasopressin receptor antagonists in heart failure.
    Hobbs RE; Tang WH
    Recent Pat Cardiovasc Drug Discov; 2006 Jun; 1(2):177-84. PubMed ID: 18232127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
    Miyazaki T; Fujiki H; Yamamura Y; Nakamura S; Mori T
    Cardiovasc Drug Rev; 2007; 25(1):1-13. PubMed ID: 17445084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular Protection and Decongestion Without Renin-Angiotensin-Aldosterone System Stimulation Mediated by a Novel Dual-Acting Vasopressin V1a/V2 Receptor Antagonist.
    Kolkhof P; Pook E; Pavkovic M; Kretschmer A; Buchmüller A; Tinel H; Delbeck M; Mondritzki T; Wasnaire P; Dinh W; Truebel H; Hüser J; Schmeck C
    J Cardiovasc Pharmacol; 2019 Jul; 74(1):44-52. PubMed ID: 31274842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolvaptan for Volume Management in Heart Failure.
    Gunderson EG; Lillyblad MP; Fine M; Vardeny O; Berei TJ
    Pharmacotherapy; 2019 Apr; 39(4):473-485. PubMed ID: 30802995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential roles of vaptans in heart failure: experience from clinical trials and considerations for optimizing therapy in target patients.
    Lin TE; Adams KF; Patterson JH
    Heart Fail Clin; 2014 Oct; 10(4):607-20. PubMed ID: 25217436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure.
    Morooka H; Iwanaga Y; Tamaki Y; Takase T; Akahoshi Y; Nakano Y; Fujiki H; Miyazaki S
    Circ Heart Fail; 2012 Jul; 5(4):484-92. PubMed ID: 22628529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arginine vasopressin receptor antagonists (vaptans): pharmacological tools and potential therapeutic agents.
    Veeraveedu PT; Palaniyandi SS; Yamaguchi K; Komai Y; Thandavarayan RA; Sukumaran V; Watanabe K
    Drug Discov Today; 2010 Oct; 15(19-20):826-41. PubMed ID: 20708094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasopressin-receptor antagonists in heart failure.
    Schweiger TA; Zdanowicz MM
    Am J Health Syst Pharm; 2008 May; 65(9):807-17. PubMed ID: 18436727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure.
    Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Kodama M; Aizawa Y
    Biochem Pharmacol; 2008 Mar; 75(6):1322-30. PubMed ID: 18179782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.
    Costello-Boerrigter LC; Smith WB; Boerrigter G; Ouyang J; Zimmer CA; Orlandi C; Burnett JC
    Am J Physiol Renal Physiol; 2006 Feb; 290(2):F273-8. PubMed ID: 16189291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemodynamic and Hormonal Effects of Tolvaptan for Heart Failure.
    Kiuchi S; Ikeda T
    Intern Med; 2019 Feb; 58(4):471-475. PubMed ID: 30210135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. V2 receptor antagonism with tolvaptan in heart failure.
    Costello-Boerrigter LC; Boerrigter G; Burnett JC
    Expert Opin Investig Drugs; 2007 Oct; 16(10):1639-47. PubMed ID: 17922627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolvaptan for the treatment of hyponatremia and congestive heart failure.
    Ferrer E
    Drugs Today (Barc); 2010 Mar; 46(3):163-71. PubMed ID: 20467590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.